Mark Newman, Author at Endocrine News

GLP-1s

Beyond the Scale: What Else Glucagon-like Peptide-1 Receptor Agonists Can Do

In the United States, American Hearth Month is observed in February to raise awareness about cardiovascular disease, the leading cause of death worldwide. To a similar end, Endocrine News focuses on a few recent journal studies that take a closer look at the impacts of incretin-based therapies in the setting of obesity and impaired cardiovascular...

New Research Challenges Fears of Semaglutide-Linked Thyroid Cancer Risk

The “black box” warning on the popular diabetes and weight loss drug semaglutide may be shifting from a cautionary black to a reassuring grey. A landmark study published in The Journal of Clinical Endocrinology & Metabolism reveals that semaglutide does not promote thyroid cancer; instead, it may suppress tumor growth by “reprogramming” the immune system...

Lilly’s Oral GLP-1 Orforglipron Demonstrates Superiority in Phase 3 Diabetes Trials

Eli Lilly’s “Ozempic-in-a-pill” candidate just cleared its most significant clinical hurdle to date. The pharmaceutical giant announced that its experimental once-daily pill, orforglipron, met all primary and secondary endpoints in two pivotal Phase 3 trials: ACHIEVE-2 and ACHIEVE-5. Data indicate that this oral treatment provides superior glycemic control compared to both a standard SGLT-2 inhibitor...

Society News

Endocrine Society Launches Rare Endocrine Disease Fellows Program

The Endocrine Society is pleased to announce its Rare Endocrine Disease (RED) Fellows Program, a series designed to equip early-career physicians with the knowledge and practical skills needed to improve outcomes for people living with rare endocrine diseases. The program was developed in partnership with the National Organization for Rare Disorders (NORD) and addresses critical gaps in awareness, diagnosis and care of rare endocrine diseases. The program consists of two core components: The program accepts up...

Novo Nordisk’s OASIS 4 Study Validates Daily Oral Pill for Chronic Weight Management

A new year brings a new therapeutic milestone for weight management: Following its recent U.S. Food and Drug Administration approval, the 25 mg oral semaglutide tablet (brand name: Wegovy), a once-daily pill became available in the United States in early January 2026 for chronic weight management and for reducing the risk of major adverse cardiovascular...

Editor's Page

And Just Like That, It’s 2026!

As we leave 2025 behind and look forward to the new year ahead, what better way to kick off 2026 than with a multi-page tribute to the latest class of Endocrine Society Laureate Award winners? In “Meet the 2026 Laureates,” we feature this year’s stellar array of legends of endocrinology from around the world. This...

Advocacy
- Clinical
- Research

Society Advocates for NIH Funding as Next Year’s Budget Process Kicks Off

As this article went to press, Congress has yet to complete a full-year spending bill for the current fiscal year (FY 2026) to fund the National Institutes of Health (NIH). This ongoing uncertainty has impacted NIH’s ability to award grants, with consequences for our member scientists and their work. Meanwhile, the Trump administration aims to release their...

Thyroid News and Research Articles

The Butterfly Effect: JCEM CR Studies Connect the Heart and the Thyroid

Nicknamed the “butterfly gland” due to its shape, the thyroid’s impact on the body is far reaching. Usually associated with growth and metabolism, recent studies published in The Journal of Clinical Endocrinology & Metabolism – Case Reports show how thyroid dysfunction can impact the heart. The common phrase “heart in my throat” usually refers to...